Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing active performance, with significant gains in key stocks and positive forecasts for companies like WuXi AppTec, indicating a strong recovery in the CRO and CDMO demand side, alongside a potential "Davis Double Play" for the sector [1] Group 1: Market Performance - As of 15:00 on January 13, the Hang Seng Biotechnology Index and the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index both rose by 1.0% [1] - Notable stock performances include WuXi AppTec rising over 7%, WuXi Biologics increasing over 5%, and Weigao Group and WuXi AppTec's subsidiary rising over 3% [1] Group 2: Company Forecasts - WuXi AppTec announced a profit forecast for the fiscal year 2025, expecting a net profit attributable to shareholders of 19.151 billion yuan, representing a year-on-year growth of approximately 102.65% [1] - Institutions predict that WuXi AppTec's order growth will continue to outpace global peers in 2026, indicating strong market positioning [1] Group 3: Industry Insights - According to Zhongtai Securities, multiple factors are driving a gradual recovery in the demand side for CRO and CDMO within the pharmaceutical sector, combined with a supply-side clearance over the past three years [1] - The Hang Seng Biotechnology Index focuses on leading biotechnology firms within the Hong Kong Stock Connect, covering various sub-sectors including biotechnology, pharmaceuticals, and medical devices [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index targets leading companies in the pharmaceutical and health industry, encompassing medical devices and innovative drugs [1] Group 4: Investment Tools - The E Fund Hang Seng Biotechnology ETF (159105) and the E Fund Hong Kong Stock Connect Pharmaceutical ETF (513200) track the aforementioned indices, providing diversified investment tools for investors to capitalize on opportunities in the pharmaceutical industry [2]

Group 1 - The core viewpoint of the article highlights the strong market interest in the chemical CDMO sector, particularly regarding Chinese companies' advantages in talent, chemical capabilities, compliance capacity, and intellectual property protection [1] - According to Guosen Securities, Chinese enterprises in the chemical CDMO field are expected to maintain a strong irreplaceable position over the next five years, especially compared to European and Indian counterparts [1] - The domestic leader WuXi AppTec is increasing its global market share in the CRDMO sector, indicating competitive dynamics among China, Europe, the US, Japan, and South Korea in the biopharmaceutical CDMO space [1] Group 2 - The "Biological Safety Act" is expected to have a mild impact in the short term, but long-term attention is needed on the restructuring of the global biopharmaceutical supply chain and the implementation of the act's details, which may affect the international business of Chinese CXO companies [1] - The Chinese innovative drug industry is projected to have a long-term positive outlook, with explosive growth in BD transactions, and external licensing being a starting point for global development [1] - The Guotai Innovation Drug ETF (517110) tracks the SHS Innovation Index (931409), which selects innovative pharmaceutical companies from the Shanghai, Shenzhen, and Hong Kong markets, focusing on those with outstanding R&D capabilities and growth potential [1]

Core Insights - The Chinese healthcare industry has undergone a significant transformation from 2020 to 2025, transitioning from a "golden era" of investment to a "bubble-clearing period" characterized by a K-shaped divergence in market performance [1][2][4]. Group 1: K-shaped Downward Trends - The collapse of previously successful business models, particularly in CXO, consumer healthcare, and internet healthcare, has led to substantial market value losses, with some companies experiencing declines of over 90% [4][7]. - The downturn is attributed to macroeconomic factors such as U.S. interest rate hikes and geopolitical tensions, as well as microeconomic issues like supply-demand imbalances and the disappearance of growth dividends [8][10]. - The CXO sector, once seen as a perpetual growth engine, has faced a 46.68% decline for WuXi Biologics and 44.47% for Tigermed, revealing the fragility of its business model reliant on continuous global financing [12][10]. - Consumer healthcare has suffered a "Davis double whammy," with companies like Yonghe Medical and Aier Eye Hospital seeing declines of 86.19% and 52.69%, respectively, as consumer spending shifts away from discretionary healthcare services [14][15]. - Internet healthcare companies, including Zhiyun Health and Dingdang Health, have also faced severe declines, with drops of 92.44% and 90.67%, as the market realizes that their revenue largely comes from online drug sales rather than innovative healthcare solutions [19][21]. Group 2: K-shaped Upward Trends - In contrast, companies with strong global rights and hard-core technology have thrived, with Keren Biotechnology and Kangfang Biopharma seeing increases of 518.33% and 166.72%, respectively, marking a shift towards biopharma and global market engagement [29][31]. - The rise of these companies signifies a new era where capital is attracted to firms that can demonstrate robust clinical data and global market potential, moving away from mere concepts [30][31]. - Even within struggling sectors, some companies like WuXi AppTec and Yuyue Medical have shown resilience, with increases of 113.36% and 28.75%, respectively, by focusing on high-tech, high-barrier services [34][35]. Group 3: Challenges Ahead - Despite the emergence of new leaders, significant challenges remain, including the risks associated with licensing agreements that may compromise long-term profitability [36][37]. - The ADC sector is experiencing a rush similar to the past PD-1 craze, raising concerns about market saturation and price competition, which could undermine future profitability [39][40]. - The ongoing "ice age" in the primary market poses a threat to innovation, as funding for early-stage companies has become increasingly scarce, potentially leading to a decline in new drug approvals in the coming years [42][43].

Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical sector, indicating a positive outlook compared to the broader market [2][4]. Core Insights - The pharmaceutical sector has shown strong performance, with the SW Pharmaceutical Biotechnology Index rising by 7.81% in the week of January 5-11, significantly outperforming the CSI 300 Index, which increased by 2.79% [2]. - Key drivers of this growth include advancements in brain-computer interfaces, small nucleic acids, and AI healthcare technologies [2]. - The report emphasizes the potential of innovation in overseas markets and hard technology, particularly in AI healthcare and brain-computer interfaces, as major growth areas for the pharmaceutical industry in 2026 [2]. Summary by Sections Industry Overview - The pharmaceutical sector is expected to continue its positive trajectory into 2026, driven by innovation and technological advancements [1]. - The report highlights the importance of the "AI + Health" investment trend, particularly with the launch of the Ant Group's "Afu" app, which focuses on health management [1][2]. Market Performance - The report notes that various sub-sectors, including hospitals, CXO, and medical devices, have experienced significant gains, with increases of 13.92%, 11.15%, and 10.81% respectively [2]. - The Hong Kong market has also seen a rebound in innovative drugs, with the Hang Seng Biotechnology Index rising by 11.06% [2]. Future Outlook - The report identifies three main sources of growth for the pharmaceutical industry: innovation in overseas markets, structural growth under the medical insurance payment framework, and natural growth from government finance and personal demand [2]. - Investment opportunities are expected to arise from the expansion of innovative drugs, hard technology, and the ongoing development of AI healthcare applications [2].

Core Viewpoint - The innovative pharmaceutical stocks have shown significant gains, driven by the upcoming 44th JPMorgan Healthcare Conference, where multiple Chinese innovative drug companies are set to participate [1] Group 1: Stock Performance - Innovent Biologics (01530) increased by 6.35%, trading at HKD 28.82 [1] - WuXi AppTec (02359) rose by 7.22%, trading at HKD 118.8 [1] - Lepu Biopharma-B (02157) saw a rise of 6.64%, trading at HKD 28.9 [1] - Galenica-B (01672) increased by 4.09%, trading at HKD 12.97 [1] - Genscript Biotech (01952) rose by 3.97%, trading at HKD 40.84 [1] Group 2: Conference Participation - The 44th JPMorgan Healthcare Conference is set to begin on January 12, 2026, in San Francisco, with several Chinese innovative drug companies confirming their attendance [1] - Key speakers include WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiary, along with innovative drug companies such as BeiGene, Zai Lab, Ascentage Pharma, and Legend Biotech [1] - A total of 17 companies, including Hengrui Medicine, Baillie Gifford, Innovent Biologics, and Rongchang Biologics, will participate in the Asia-Pacific session [1] Group 3: Industry Insights - According to Guojin Securities, the conference serves as a critical platform for domestic pharmaceutical companies to showcase their core molecular product capabilities and advance overseas business development collaborations [1] - The industry is transitioning back to a phase of global value verification for products, with ongoing clinical advancements, significant data releases, and improved competitive dynamics driving multiple rounds of revaluation for product global value and corporate valuations [1] - Huayuan Securities indicates that the Chinese pharmaceutical industry has largely completed the transition from old to new growth drivers, with innovative drugs significantly opening new growth trajectories for companies [1]

个股消息面上，药明康德发布2025年度业绩预告，预计归属于上市公司股东的净利润为191.51亿元，同 比增长约103%，其中包含了出售联营公司部分股权以及剥离部分业务所获得的投资收益；本期基本每 股收益预计约人民币6.70元/股，同比增长约104.27%。 个股消息面上，药明康德发布2025年度业绩预告，预计归属于上市公司股东的净利润为191.51亿元，同 比增长约103%，其中包含了出售联营公司部分股权以及剥离部分业务所获得的投资收益；本期基本每 股收益预计约人民币6.70元/股，同比增长约104.27%。 责任编辑：郝欣煜 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 1月13日消息，港股创新药概念盘初拉升，药明康德涨超9%，博安生物、三生制药涨超8%，药明生 物、乐普生物涨超6%，复星医药、药明合联、翰森制药涨超4%。 1月13日消息，港股创新药概念盘初拉升，药明康德涨超9%，博安生物、三生制药涨超8%，药明生 物、乐普生物涨超6%，复星医药、药明合联、翰森制药涨超4%。 责任编辑：郝欣煜 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 ...

Group 1: Core Insights - WuXi AppTec (药明合联) has been selected as a representative in the "Top Ten Core Assets" in the Chinese pharmaceutical industry for 2026, highlighting its significance in the global market [1] - The company was established in 2021 as a joint venture between WuXi Biologics and WuXi AppTec, focusing on ADC CDMO services, and officially listed on the Hong Kong Stock Exchange in November 2023 [1] - WuXi AppTec has become the second-largest ADC CDMO supplier globally, with market share increasing from 1.8% in 2020 to 22% in the first half of 2025 [1][23] Group 2: Industry Background - The Chinese pharmaceutical industry has undergone a significant transformation over the past decade, evolving from a focus on generics to becoming a major contributor to global pharmaceutical innovation [3] - The rapid development of innovative drugs in China is driven by policy support, capital investment, and talent development, transitioning from cost and efficiency advantages to technological leadership [3] - The cumulative overseas licensing transaction value for innovative drugs has surpassed $130 billion, indicating China's shift from a generic drug manufacturing powerhouse to an innovative drug exporter [4] Group 3: ADC Market Dynamics - The ADC market is expected to grow significantly, with projections indicating a market size of $13.5 billion in 2024, reaching $150.2 billion by 2033, and ADC's share of the overall oncology market increasing from 5.2% to 27.3% during the same period [9] - The production of ADCs is complex and requires precise control, leading to high technical barriers that necessitate reliance on specialized CDMO services [10] - The global ADC outsourcing market is projected to grow from approximately $1.5 billion in 2022 to $11 billion by 2030, with a compound annual growth rate of 28.4% [10] Group 4: Company Performance and Strategy - WuXi AppTec offers integrated CRDMO services for ADCs, providing end-to-end solutions that reduce communication costs and enhance R&D speed for pharmaceutical companies [14] - The company's revenue for the first half of 2025 increased by 62.2% to 2.7 billion yuan, with net profit rising by 52.74% to 746 million yuan [14] - As of mid-2025, WuXi AppTec had executed 858 discovery projects, with 225 ongoing projects, including 103 in clinical and commercialization stages, capturing 30% to 35% of the global clinical pipeline market [17] Group 5: Future Outlook - The company is strategically expanding its ADC CDMO capacity in Singapore and China, with planned capital expenditures exceeding 1.5 billion yuan in 2024 and 2025 to meet growing market demand [24] - Revenue forecasts for WuXi AppTec indicate growth to 5.965 billion yuan in 2025, 8.058 billion yuan in 2026, and 10.422 billion yuan in 2027, with corresponding net profit projections of 1.555 billion yuan, 2.114 billion yuan, and 2.798 billion yuan [27] - The increasing demand for R&D and production outsourcing in the pharmaceutical sector is expected to stabilize and grow, contributing to the company's future profitability [26]

Core Viewpoint - WuXi AppTec (02268.HK) has been selected as one of the "Top Ten Core Assets" in the 2026 "Betting on China" list, representing the traditional Chinese medicine industry [2] Group 1: Company Overview - WuXi AppTec was established in 2021 as a joint venture between WuXi Biologics and WuXi AppTec, providing ADC CDMO services and officially listed on the Hong Kong Stock Exchange in November 2023 [3] - The company has become the second-largest ADC CDMO supplier globally, with market share increasing from 1.8% in 2020 to 22% in the first half of 2025 [3][39] Group 2: Industry Background - The rapid development of China's innovative pharmaceutical industry is attributed to policy guidance, capital support, and talent backing, transitioning from a "cost + efficiency" advantage to a technology-leading advantage [9] - The global ADC market is expected to grow significantly, with projections indicating a market size of $13.5 billion in 2024 and $150.2 billion by 2033, with ADC's share of the overall oncology market rising from 5.2% to 27.3% during the same period [18] Group 3: Business Performance - WuXi AppTec's revenue for the first half of 2025 increased by 62.2% to 2.7 billion yuan, with net profit rising by 52.74% to 746 million yuan [27] - The company has executed a total of 858 discovery projects since its inception, with 225 ongoing projects, including 103 in clinical and commercialization stages [30][31] - The company holds a 30% to 35% market share in clinical pipelines globally and has partnerships with 13 of the top 20 pharmaceutical companies [32] Group 4: Future Outlook - The company is expected to continue expanding its production capacity in Wuxi and Singapore, with capital expenditures exceeding 1.5 billion yuan in 2024 and 2025, aiming to double its production capacity by 2029 [39] - Revenue projections for WuXi AppTec are expected to reach 5.97 billion yuan in 2025, 8.06 billion yuan in 2026, and 10.42 billion yuan in 2027, with corresponding growth rates of 47.2%, 35.08%, and 29.35% [40][45] Group 5: Investment Thesis - Investing in WuXi AppTec is essentially a bet on the enhancement of global competitiveness of Chinese innovative drugs and the supporting CXO industry chain [52]

Investment Rating - The industry investment rating is "Buy" for companies such as 三生制药 (1530 HK), 固生堂 (2273 HK), 药明合联 (2268 HK), and 中国生物制药 (1177 HK) [3][4][32]. Core Insights - The MSCI China Healthcare Index has increased by 11.8% since the beginning of 2026, outperforming the MSCI China Index which rose by 9.1%. The pharmaceutical sector has seen significant growth due to strong institutional investor interest at the start of the year following a valuation correction in Q4 of the previous year [2]. - The trend of innovative drugs going overseas is expected to continue in the long term, with a focus on the clinical progress and data validation of pipelines that have already gone abroad [2]. - The domestic innovative drug market is still relatively small, with an estimated market size of 300-400 billion RMB, of which domestic innovative drugs account for about 1/3, or 100-130 billion RMB. If the proportion of patented drugs in China reaches 66% like the global average, the market size could potentially reach around 760 billion RMB [6]. Summary by Sections Company Recommendations - Recommended companies for investment include 三生制药 (1530 HK), 固生堂 (2273 HK), 药明合联 (2268 HK), and 中国生物制药 (1177 HK) [3][4]. Market Trends - The market for domestic innovative drugs is characterized by high demand due to aging populations, weak pricing from insurance negotiations, strong competition, and short product life cycles. The global pharmaceutical market is projected to reach 1.74 trillion USD in 2024, with China's market size at 166 billion USD, representing only 9.5% of the global market [6]. - The potential market size for domestic innovative drugs going abroad could reach 110 billion USD, nearly 800 billion RMB, if one-third of the global patented drug market is sourced from China [6]. Clinical Development and Financials - In 2025, the total transaction amount for BD (business development) licensing for Chinese innovative drugs is expected to reach 135.65 billion USD, a year-on-year increase of 161%, with 70 million USD in upfront payments [6]. - Basic medical insurance expenditure showed a slight recovery in 2025, with cumulative spending growth of 0.5% and income growth of 2.9%, indicating a shift in the growth catalyst from insurance to out-of-pocket and commercial insurance [6].

Core Insights - The Huabao CSI Hong Kong Stock Connect Medical Theme ETF (159137) closed with a gain of 0.38% on January 12, with a trading volume of 173 million yuan [1] Fund Overview - The fund was established on December 31, 2025, and is officially named Huabao CSI Hong Kong Stock Connect Medical Theme Exchange-Traded Fund [1] - The management fee is set at 0.50% per annum, while the custody fee is 0.10% per annum [1] - The performance benchmark for the fund is the return of the CSI Hong Kong Stock Connect Medical Theme Index, adjusted for the RMB exchange rate [1] Fund Management - The current fund manager is Zhang Fang, who has managed the fund since its inception, achieving a return of 4.33% during the management period [1] Top Holdings - The latest report indicates that the top holdings of the ETF include: - WuXi Biologics: 2.65% holding, valued at approximately 7.49 million yuan [2] - JD Health: 2.02% holding, valued at approximately 5.71 million yuan [2] - WuXi AppTec: 1.44% holding, valued at approximately 4.07 million yuan [2] - Crystal Digital Holdings: 0.98% holding, valued at approximately 2.76 million yuan [2] - Alibaba Health: 0.93% holding, valued at approximately 2.63 million yuan [2] - WuXi AppTec Holdings: 0.86% holding, valued at approximately 2.43 million yuan [2] - Sinopharm: 0.72% holding, valued at approximately 2.04 million yuan [2] - Genscript Biotech: 0.55% holding, valued at approximately 1.55 million yuan [2] - Ping An Good Doctor: 0.46% holding, valued at approximately 1.31 million yuan [2] - CSPC Pharmaceutical Group: 0.41% holding, valued at approximately 1.17 million yuan [2]